Antibiotic resistance has emerged as one of the top ten global health challenges according to the World Health Organization (WHO). A significant contributor to this issue is the misuse and overuse of antibiotics. Traditional Antibiotic Susceptibility Testing (AST) methods, which facilitate evidence-based antibiotic selections, typically necessitate external microbiology labs and have a turnaround time exceeding two days. Consequently, healthcare providers often resort to prescribing broad-spectrum, first-line antibiotics, which are later adjusted based on laboratory results. This standard of care in managing bacterial infections is inadequate, adversely affecting patient outcomes and exacerbating antibiotic resistance.
ShanX Medtech BV (Netherlands), under the leadership of Dr. Sophia E. Shanko, is innovating a novel AST device that delivers results in as little as one hour and directly at the point of care. This groundbreaking system is set to transform clinical microbiology testing. As with any significant advancement, comprehensive studies involving various stakeholders are essential for successful market introduction and acceptance.
In this Women TechEU proposal, Dr. Shanko and the ShanX Medtech team have analyzed market dynamics, engaged Key Opinion Leaders, and identified purchasing drivers. The outcome of this project is a well-defined market position and a collection of term sheets resulting from successful fundraising efforts.
